ArticleJournal of medical biochemistry2025
Serum estradiol (E2), progesterone (P), and human chorionic gonadotropin (HCG), D-dimer (D-D) fibrinogen (FIB) levels after low molecular weight heparin sodium on preventing miscarriage in patients with adverse pregnancy and delivery.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study investigates the effects of subcutaneous injection of low molecular weight heparin (LMWH) sodium on preventing miscarriage in patients with adverse pregnancy and delivery. Specifically, it evaluates changes in serum estradiol (E2), progesterone (P), and human chorionic gonadotropin (HCG), as well as D-dimer (D-D) and fibrinogen (FIB) levels following treatment. Methods: A total of 82 patients with adverse pregnancy admitted to Wuhai Maternal and Child Health Hospital from April to December 2024 were randomly assigned to either the control group (CG, n=41) receiving dydroges-terone therapy or the observation group (OG, n=41), which received LMWH sodium in addition to dydroges-terone. The study assessed changes in sex hormone levels, pre-thrombotic state (PTS) indices, thromboelastogram (TEG) parameters, and overall treatment outcomes before and after treatment. Results: Following treatment, E2, P, and HCG levels were significantly higher in the OG compared to the CG (P<0.05). Additionally, coagulation markers such as activated partial thromboplastin time (APTT), prothrombin time (PT), thrombin time (TT), and plasminogen (PLG) were significantly elevated in the OG, while FIB and D-D levels were lower compared to the CG (P<0.05). TEG analysis showed that the OG exhibited higher R and K values, whereas MA, Angle, and CI values were lower than in the CG (P<0.05). The total response rate in the OG (95.12%) was significantly higher than in the CG (75.61%) (P<0.05). Additionally, the OG had lower rates of neonatal malformation, low birth weight, and mortality compared to the CG, with significant differences in malformation and low birth weight rates (P<0.05). Conclusions: Subcutaneous injection of LMWH sodium effectively improves sex hormone levels, reduces the risk of PTS, and enhances pregnancy outcomes in patients with adverse pregnancy and delivery. The therapy also improves coagulation and fibrinolytic markers, leading to better maternal and neonatal outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.